Last reviewed · How we verify
Nasal Glucagon (NG)
Nasal glucagon activates glucagon receptors to rapidly increase blood glucose levels in hypoglycemic emergencies.
Nasal glucagon activates glucagon receptors to rapidly increase blood glucose levels in hypoglycemic emergencies. Used for Severe hypoglycemia in patients with diabetes.
At a glance
| Generic name | Nasal Glucagon (NG) |
|---|---|
| Also known as | Nasal Glucagon, AMG504-1 Dry-Mist Intranasal Glucagon, LY900018 |
| Sponsor | Eli Lilly and Company |
| Drug class | Glucagon receptor agonist |
| Target | Glucagon receptor (GCGR) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | Phase 3 |
Mechanism of action
Glucagon is a hormone that binds to glucagon receptors on hepatic cells, stimulating glycogenolysis and gluconeogenesis to raise blood glucose. The nasal formulation allows rapid absorption through the nasal mucosa, enabling quick glucose elevation without requiring intravenous administration. This provides a non-invasive alternative to injectable glucagon for acute hypoglycemia treatment.
Approved indications
- Severe hypoglycemia in patients with diabetes
Common side effects
- Nausea
- Vomiting
- Headache
- Nasal irritation
Key clinical trials
- A Study Comparing User Experience of Different Delivery Devices for Glucagon (PHASE1)
- A Study of Single and Repeated Doses of Glucagon Administered to Participants With Diabetes (PHASE1)
- A Study of Single or Repeated Doses of Glucagon in Participants With Diabetes (PHASE1)
- Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia (PHASE2)
- A Study of Glucagon Administered in Different Forms and Routes to Healthy Adults (PHASE1)
- A Study of Nasal Glucagon in Participants With a Common Cold (PHASE1)
- Evaluate the Immunogenicity of a Novel Glucagon Formulation (PHASE3)
- Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nasal Glucagon (NG) CI brief — competitive landscape report
- Nasal Glucagon (NG) updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI